HIV Resistance, Molecular Epidemiology and New Treatment Strategies in the Eastern European Region and in Russia
This study focuses on understanding how the HIV virus in Eastern Europe and Russia might become resistant to new treatments. Researchers are carefully watching a group of people with HIV to see if their virus changes and becomes harder to treat, particularly as new anti-HIV drugs are released. By collecting information about the virus and how patients are doing, they hope to learn more about the spread of drug resistance. This knowledge will help doctors make better treatment choices in the future and improve care for people living with HIV. The study also aims to understand different types of HIV found in these regions and how they respond to various medications, including newer and older ones.
At a glance
What is this study about?
This study is about understanding how the Human Immunodeficiency Virus (HIV) behaves and changes, especially in parts of Eastern Europe and Russia. When new medicines to treat HIV become available, it's really important to keep an eye on how the virus responds. Sometimes, viruses can adapt and become resistant, meaning the medicines don't work as well.
Researchers are collecting information from a group of people with HIV, both about their health and the virus itself. This allows them to track if the virus develops resistance to the new drugs, particularly a type called INSTI. They also want to understand the different kinds of HIV found in these areas and how they spread. All of this information helps build a clearer picture of how HIV is evolving and what impact this has on treatment.
The main goal is to gather vital information that will help doctors and health organisations provide the best possible care for people with HIV. By understanding drug resistance patterns and how different HIV types behave, future treatments can be planned more effectively, ensuring medicines continue to work well for as many people as possible.
Key takeaways
- The study tracks how HIV changes, especially resistance to new treatments.
- It focuses on patients in Eastern Europe and Russia to improve local care.
- Researchers collect blood samples and health information over time.
- The goal is to help doctors choose better HIV treatments in the future.
- No new medicines are given as part of this study.
- It requires long-term commitment for monitoring.
Who may be eligible?
To join this study, you would need to be an adult, 18 years or older, who has HIV. Specifically, you should be starting a new type of HIV treatment called a 'second-generation INSTI' for the first time.
Alternatively, you might be eligible if you're already on this type of INSTI treatment for the first time, and there's a record of your HIV virus from before you started treatment, or a blood sample available from within the last three years that shows you haven't had any treatment problems before or since.
There are a couple of reasons you wouldn't be able to join. Firstly, if you can't or don't want to sign a form that allows your health information to be stored for the study, then you wouldn't be able to take part. Also, if you are under 18 years old when the study starts, you wouldn't be eligible.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you about to start a new HIV treatment called a 'second-generation INSTI'?
- Or, have you recently started a 'second-generation INSTI' and have old blood test results available?
- Are you able to sign a consent form for your health information to be used for research?
What does participation involve?
The study involves providing samples and health information mainly related to your HIV infection and treatment. Researchers will collect details about your virus from samples, likely blood, and combine this with your medical history and how your treatment is progressing. This is a monitoring study, meaning it will involve ongoing collection of data over time to see how the virus changes. You will continue to receive your standard HIV treatment as prescribed by your doctor. The study itself does not involve new medications beyond what your doctor would normally recommend. There isn't a specific end date mentioned for individual participation, as it aims for both short-term and long-term follow-up to track changes over time.
Potential risks and benefits
Locations (4)
- University Hospital of CologneVerified postcodeCologne, Germany· Recruiting
- University Hospital of SienaVerified postcodeSiena, Italy· Recruiting
- Pomeranian Medical University SzczecinVerified postcodeSzczecin, Poland· Recruiting
- Karolinska InstitutetVerified postcodeStockholm, Sweden· Recruiting
Common questions
What is HIV drug resistance?
HIV drug resistance means the virus has changed, so the medicines you take to treat it no longer work as well as they should.
Why is this study important for people in Eastern Europe and Russia?
It's important because understanding how HIV changes in these specific areas helps doctors choose the best treatments for people there and improve public health.
Will I get new medicine in this study?
No, this study doesn't give you new medicines. It monitors how the HIV virus responds to treatments you're already taking or are about to start, especially newer ones.
Is my personal information kept private?
Yes, all your personal and health information collected for the study will be kept confidential and secure.
How long will I be followed in this study?
The study involves both short-term and long-term follow-up, meaning researchers will track your information over a period of time to see how things change.
How to find out more
FRANCESCA INCARDONA
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.